Q-omics provides the consensus-scored PGAM1P5 profile across patient tissues and cancer cell-line models. PGAM1P5 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PGAM1P5 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PGAM1P5 RNA expression shows 16,401 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, and KIRP as cancer lineages where PGAM1P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PGAM1P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PGAM1P5 survival associations across molecular data types. PGAM1P5 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PGAM1P5 RNA expression–survival associations across cancer types. High PGAM1P5 expression shows unfavorable associations in ACC, but favorable associations in KIRC, BLCA, LGG, THYM and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PGAM1P5 RNA expression.
This table summarizes PGAM1P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PGAM1P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PGAM1P5 shows lower tumor expression in KIRC, LUSC, KICH, LUAD and KIRP and higher tumor expression in COAD. The KIRC box plot shows higher PGAM1P5 RNA expression in normal versus tumor tissue (log2 FC = −0.335, t-test p < 0.001).
This table shows molecular features associated with PGAM1P5 in patient tissues and cancer cell lines. In patient samples, PGAM1P5 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, PGAM1P5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD.
